Compare LOB & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LOB | IOVA |
|---|---|---|
| Founded | 2008 | 2007 |
| Country | United States | United States |
| Employees | 1040 | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 2014 | 2008 |
| Metric | LOB | IOVA |
|---|---|---|
| Price | $43.45 | $6.89 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $43.00 | $9.00 |
| AVG Volume (30 Days) | 206.4K | ★ 18.1M |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.32% | N/A |
| EPS Growth | ★ 31.95 | 14.84 |
| EPS | ★ 1.35 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $35.52 | $47.74 |
| Revenue Next Year | $16.03 | $40.31 |
| P/E Ratio | $32.10 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $29.36 | $1.76 |
| 52 Week High | $44.53 | $6.92 |
| Indicator | LOB | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 57.75 | 71.21 |
| Support Level | $39.86 | $3.57 |
| Resistance Level | $44.19 | $6.92 |
| Average True Range (ATR) | 1.01 | 0.43 |
| MACD | -0.09 | 0.18 |
| Stochastic Oscillator | 58.36 | 93.75 |
Live Oak Bancshares Inc operates as the bank holding company for the Live Oak Banking Company. The company specializes in lending and deposit-related services to small businesses nationwide. The company identifies and extends lending to credit-worthy borrowers both within specific industries, also called verticals, through expertise within those industries, and more broadly to select borrowers outside of those industries. A portion of the loans originated by the Bank are partially guaranteed by the Small Business Administration under the 7(a) Loan Program and the U.S. Department of Agriculture Rural Energy for America Program, Water and Environmental Program, Business and Industry and Community Facilities loan programs.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.